137 related articles for article (PubMed ID: 11269747)
21. [Taxotere: from yew's needles to clinical practice].
Lavelle F; Gueritte-Voegelein F; Guenard D
Bull Cancer; 1993 Apr; 80(4):326-38. PubMed ID: 7909695
[TBL] [Abstract][Full Text] [Related]
22. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
23. Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.
Morgan KM; Fischer BS; Lee FY; Shah JJ; Bertino JR; Rosenfeld J; Singh A; Khiabanian H; Pine SR
Mol Cancer Ther; 2017 Dec; 16(12):2759-2769. PubMed ID: 28978720
[TBL] [Abstract][Full Text] [Related]
24. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
Cassinelli G; Supino R; Perego P; Polizzi D; Lanzi C; Pratesi G; Zunino F
Int J Cancer; 2001 Jun; 92(5):738-47. PubMed ID: 11340581
[TBL] [Abstract][Full Text] [Related]
25. Overcoming multidrug resistance in taxane chemotherapy.
Geney R; Ungureanu lM; Li D; Ojima I
Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
[TBL] [Abstract][Full Text] [Related]
26. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
27. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
28. [Synthesis and cytotoxicity of the new taxoids].
Yao F; Guo J; Liang X
Yao Xue Xue Bao; 1998 Sep; 33(9):659-65. PubMed ID: 12016869
[TBL] [Abstract][Full Text] [Related]
29. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
30. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Bissery MC; Vrignaud P; Lavelle F
Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
[TBL] [Abstract][Full Text] [Related]
31. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Dykes DJ; Bissery MC; Harrison SD; Waud WR
Invest New Drugs; 1995; 13(1):1-11. PubMed ID: 7499102
[TBL] [Abstract][Full Text] [Related]
32. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
34. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
35. The taxanes: an update.
Crown J; O'Leary M
Lancet; 2000 Apr; 355(9210):1176-8. PubMed ID: 10791395
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
37. [New taxanes and epothilone derivatives in clinical trials].
Lavelle F
Bull Cancer; 2002 Apr; 89(4):343-50. PubMed ID: 12016034
[TBL] [Abstract][Full Text] [Related]
38. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
39. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
[TBL] [Abstract][Full Text] [Related]
40. [Taxotere in various solid tumors].
Orel NF
Vopr Onkol; 1998; 44(5):639-44. PubMed ID: 9925501
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]